TY - JOUR
T1 - Nanotechnological advances in the treatment of epilepsy
AU - Abdou Ali, Ola Asem Mahmoud
AU - Shaikh, Mohd. Farooq
AU - Hasnain, M. Saquib
AU - Sami, Farheen
AU - Khan, Abdullah
AU - Ansari, Mohammed Tahir
N1 - Publisher Copyright:
© 2022 Bentham Science Publishers.
PY - 2022/12
Y1 - 2022/12
N2 - Epilepsy is known as one of the major challenges for medical science. The sudden ap-pearance of a seizure has been a significant health emergency as it may lead to further complica-tions. Although key advancements have been achieved in terms of pharmacological approaches for epilepsy, many issues remain uncertain. Lipid carriers have been at the forefront, especially in neu-rodegenerative diseases, such as epilepsy, Alzheimer’s, dementia, etc. The blood-brain barrier still appears to be a major impediment in the successful treatment of epileptic seizures. This is mainly due to the limited bioavailability of most anti-convulsant drugs. The present review encompasses the issues underlying the current approach for epilepsy drug treatment and highlights the newer, novel, and more precise drug delivery system to manage seizures. The advantage of using a lipid-based delivery system is its superior absorption in the brain cells. Ample evidence shows that reduc-ing the particle size also infuses the drug easily through the blood-brain barrier. The application of liposomes, polymeric nanoparticles, metallic nanoparticles, and solid lipid nanoparticles for the treatment and management of epilepsy has been highlighted in the present review. This review pro-vides an overview of the current status of the treatment and recent advances in the treatment of epilepsy.
AB - Epilepsy is known as one of the major challenges for medical science. The sudden ap-pearance of a seizure has been a significant health emergency as it may lead to further complica-tions. Although key advancements have been achieved in terms of pharmacological approaches for epilepsy, many issues remain uncertain. Lipid carriers have been at the forefront, especially in neu-rodegenerative diseases, such as epilepsy, Alzheimer’s, dementia, etc. The blood-brain barrier still appears to be a major impediment in the successful treatment of epileptic seizures. This is mainly due to the limited bioavailability of most anti-convulsant drugs. The present review encompasses the issues underlying the current approach for epilepsy drug treatment and highlights the newer, novel, and more precise drug delivery system to manage seizures. The advantage of using a lipid-based delivery system is its superior absorption in the brain cells. Ample evidence shows that reduc-ing the particle size also infuses the drug easily through the blood-brain barrier. The application of liposomes, polymeric nanoparticles, metallic nanoparticles, and solid lipid nanoparticles for the treatment and management of epilepsy has been highlighted in the present review. This review pro-vides an overview of the current status of the treatment and recent advances in the treatment of epilepsy.
KW - blood brain barrier
KW - Epilepsy
KW - liposomes
KW - metallic
KW - nanoparticles
KW - resistance
UR - https://www.scopus.com/pages/publications/85128854613
U2 - 10.2174/1871527321666211221162104
DO - 10.2174/1871527321666211221162104
M3 - Review Article
C2 - 34939554
AN - SCOPUS:85128854613
SN - 1871-5273
VL - 21
SP - 994
EP - 1003
JO - CNS & Neurological Disorders - Drug Targets
JF - CNS & Neurological Disorders - Drug Targets
IS - 10
ER -